Information  X 
Enter a valid email address

Summit Corporation PLC (SUMM)

  Print      Mail a friend

Tuesday 28 October, 2008

Summit Corporation PLC

Directorate change

Summit Corporation plc
("Summit plc" or "the Company")

Oxford, UK, 28 October 2008 -  Summit Corporation plc (AIM: SUMM),  a
leading  UK  biotechnology  company,  is  pleased  to  announce   the
appointment of  Mr Tony  Weir (age  48) as  the new  Chief  Financial
Officer and member  of the  Board of  Directors of  the Company  with
effect from 17 November 2008.

Mr Weir will join  Summit plc from Vernalis  plc (LSE: VER) where  he
held the position of  Chief Financial Officer  for almost ten  years.
During  that  time,  he  guided  the  company  through  a  range   of
transactions, including M&A, licensing deals and raising of  finance.
 He is a Fellow  of the Institute of  Chartered Accountants, holds  a
degree in Mathematics  from the University  of Oxford and  is also  a
non-executive director of Biocompatibles International plc.

Barry Price, PhD, Chairman  of Summit, commented:  "On behalf of  the
Board I would like  to welcome Tony to  Summit.  We are delighted  to
have attracted someone  of his  calibre who  will bring  considerable
financial experience  as  well as  a  deep understanding  of  the  UK
biotechnology sector.  These  qualities will be  of great  importance
for Summit in meeting the future challenges we face in continuing  to
build a successful business."

There  is  no  further  information  required  to  be  disclosed   in
accordance with  Schedule  2, paragraph  (g)  of the  AIM  Rules  for

                              - ENDS -
For more information, please contact:
Summit plc
Steven Lee, PhD, Chief Executive Officer
Richard Pye, PhD, Investor Relations
Tel: +44 (0)1235 443951; +44 (0)7825 313476
Citigate Dewe Rogerson
Mark Swallow, PhD / David Dible / Emma Palmer Foster
Tel: +44 (0)207 638 9571
Panmure Gordon
Andrew Burnett / Rakesh Sharma (Corporate Finance)
Ashton Clanfield (Corporate Broking)
Tel: +44 (0)207 459 3600

About Summit plc
Summit plc  is  a  leading  UK biotechnology  company  with  a  broad
preclinical  and  clinical  pipeline,  two  world-leading  technology
platforms and  an  innovative  business model  that  is  expected  to
generate sustainable value for investors.
Summit is  developing  multiple  drug programmes  that  target  unmet
medical  needs  from   which  it   intends  to   generate  value   by
out-licensing attractive  late preclinical  or early  clinical  stage
programmes in  return for  upfront, milestone  and royalty  payments.
Summit uses  its  scientific  expertise to  target  orphan  diseases,
neuro-disorders and infectious  diseases. Summit has  signed a  major
licensing agreement with BioMarin in Duchenne muscular dystrophy  and
has co-development  agreements  with  Evolva  (infectious  diseases),
Orient  Pharma  (sialorrhoea)  and   the  Lilly  TB  Drug   Discovery
Initiative (tuberculosis)
Underpinning Summit's  drug pipeline  are two  innovative  technology
platforms:  carbohydrate  chemistry  and  zebrafish  biology.   These
platforms support existing programmes and also will be the source  of
future  programmes  to  replenish  Summit's  drug  pipeline.    These
platform technologies also form the basis of the Company's profitable
service business.
The company listed on the alternative investment market (AIM) of  the
London Stock  Exchange  in  October 2004  -  symbol:  SUMM.   Further
information about the company is available at


This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.